ALEC250117P2500
- 0.70
- 0.000.00%
Alector Newsroom
What You Need To Know About The Alector, Inc. (NASDAQ:ALEC) Analyst Downgrade Today
Mizuho Securities Downgrades Alector(ALEC.US) to Hold Rating, Announces Target Price $2.5
Alector Price Target Announced at $4.00/Share by Stifel
Stifel Downgrades Alector(ALEC.US) to Hold Rating, Cuts Target Price to $4
Express News | Ra Capital Management, L.p. Reports 9.9% Passive Stake in Alector Inc as of Nov 29 - SEC Filing
BofA Securities Downgrades Alector(ALEC.US) to Sell Rating, Cuts Target Price to $1
Alector Shares Are Trading Lower After the Company Released Its INVOKE-2 Phase 2 Trial Results That Failed to Meet Its Primary Endpoint. Also, Bank of America Downgraded the Stock From Neutral to Underperform.
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts
BofA Securities Downgrades Alector to Underperform
A Quick Look at Today's Ratings for Alector(ALEC.US), With a Forecast Between $3 to $7
Alector Price Target Lowered to $7 From $35 at H.C. Wainwright
Express News | Alector Inc : Morgan Stanley Cuts Target Price to $3.00 From $10.00
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Poseida PSTX Merger With RHHBY; Alector ALEC Phase 2 Fails
Alector Cut to Underweight From Equal-Weight by Morgan Stanley
Alector Is Maintained at Buy by BTIG
Cantor Fitzgerald Reiterates Overweight on Alector
Alector Analyst Ratings
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
Buy Rating Maintained for Alector Despite AL002 Setback, Focus on Promising AL001 and Strong Financials